[go: up one dir, main page]

MX9708781A - Heterociclos como inhibidores de la adhesion de leucocitos y antagonistas de vla-4. - Google Patents

Heterociclos como inhibidores de la adhesion de leucocitos y antagonistas de vla-4.

Info

Publication number
MX9708781A
MX9708781A MX9708781A MX9708781A MX9708781A MX 9708781 A MX9708781 A MX 9708781A MX 9708781 A MX9708781 A MX 9708781A MX 9708781 A MX9708781 A MX 9708781A MX 9708781 A MX9708781 A MX 9708781A
Authority
MX
Mexico
Prior art keywords
compounds
formula
vla
present
leukocytes
Prior art date
Application number
MX9708781A
Other languages
English (en)
Inventor
Hans Ulrich Stilz
Volkmar Wehner
Christoph Huels
Dirk Seiffge
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of MX9708781A publication Critical patent/MX9708781A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos de la formula I: en la que B, D, E, R, W, Y, Z, b, c, d, e, f, g y h tienen los significados indicados en las reivindicaciones, son inhibidores de la adhesion y migracion de leucocitos y/o antagonistas del receptor de adhesion VLA-4 perteneciente al grupo de las integrinas. La invencion se refiere al empleo de compuestos de la formula I y de preparados farmacéuticos que contienen tales compuestos para el tratamiento o la profilaxis de enfermedades que son provocadas por un grado indeseado de adhesion de leucocitos y/o migracion de leucocitos o que están ligadas a ellas, o en las que juegan un papel interacciones célula-célula-matriz que se basan en interacciones de receptores VLA-4 con sus ligandos, por ejemplo de procesos inflamatorios, la artritis reumatoide o de enfermedades alérgicas, al igual que al empleo de compuestos de la formula I para la preparacion de medicamentos para empleo en enfermedades de este tipo. Además, se refiere a nuevos compuestos de la formula I.
MX9708781A 1996-11-15 1997-11-14 Heterociclos como inhibidores de la adhesion de leucocitos y antagonistas de vla-4. MX9708781A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19647382A DE19647382A1 (de) 1996-11-15 1996-11-15 Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten

Publications (1)

Publication Number Publication Date
MX9708781A true MX9708781A (es) 1998-05-31

Family

ID=7811832

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9708781A MX9708781A (es) 1996-11-15 1997-11-14 Heterociclos como inhibidores de la adhesion de leucocitos y antagonistas de vla-4.

Country Status (28)

Country Link
US (2) US5998447A (es)
EP (1) EP0842944B1 (es)
JP (1) JP4510160B2 (es)
CN (1) CN1133647C (es)
AR (1) AR010066A1 (es)
AT (1) ATE244725T1 (es)
AU (1) AU736595B2 (es)
BR (1) BR9705726A (es)
CA (1) CA2220822A1 (es)
CZ (1) CZ292521B6 (es)
DE (2) DE19647382A1 (es)
DK (1) DK0842944T3 (es)
ES (1) ES2202533T3 (es)
HR (1) HRP970606B1 (es)
HU (1) HUP9702034A3 (es)
IL (1) IL122186A (es)
MX (1) MX9708781A (es)
MY (1) MY118176A (es)
NO (1) NO317242B1 (es)
NZ (1) NZ329177A (es)
PL (2) PL323130A1 (es)
PT (1) PT842944E (es)
RU (1) RU2220977C2 (es)
SI (1) SI0842944T1 (es)
SK (1) SK284349B6 (es)
TR (1) TR199701356A2 (es)
TW (1) TW580501B (es)
ZA (1) ZA9710245B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19647382A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647380A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19741235A1 (de) * 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) * 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ509241A (en) 1998-08-07 2003-08-29 Du Pont Pharm Co Succinoylamino lactams as inhibitors of alpha-beta protein production
CA2347671A1 (en) 1998-12-24 2000-07-06 Dupont Pharmaceuticals Company Succinoylamino benzodiazepines as inhibitors of a.beta. protein production
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
AU7997700A (en) 1999-10-08 2001-04-23 Du Pont Pharmaceuticals Company Amino lactam sulfonamides as inhibitors of abeta protein production
KR20020067050A (ko) 1999-12-28 2002-08-21 화이자 프로덕츠 인코포레이티드 염증성, 자기면역 및 호흡기 질환의 치료에 유용한브이엘에이-4 의존성 세포 결합의 비펩티드계 억제제
WO2001055121A1 (en) * 2000-01-28 2001-08-02 Kaken Pharmaceutical Co., Ltd. Azepine derivatives
JP2003523345A (ja) 2000-02-17 2003-08-05 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Ａβタンパク質産生の阻害剤としてのスクシノイルアミノ炭素環および複素環
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
CA2404023A1 (en) * 2000-04-03 2001-10-11 Richard E. Olson Cyclic lactams as inhibitors of a.beta. protein production
US6713476B2 (en) 2000-04-03 2004-03-30 Dupont Pharmaceuticals Company Substituted cycloalkyls as inhibitors of a beta protein production
JP2004500419A (ja) 2000-04-11 2004-01-08 デュポン　ファーマシューティカルズ　カンパニー Ａβタンパク質産生阻害剤としての置換ラクタム
HK1049333A1 (zh) 2000-06-01 2003-05-09 Bristol-Myers Squibb Pharma Company 以环状琥珀酸酯代替内酰胺，作为制造Aβ蛋白质的抑制剂
AU2001268607A1 (en) * 2000-06-21 2002-01-02 Bristol-Myers Squibb Company Piperidine amides as modulators of chemokine receptor activity
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
DE10111877A1 (de) * 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
TW200307667A (en) * 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
FR2866886B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique
KR101155335B1 (ko) * 2005-01-07 2012-06-11 엘지전자 주식회사 이동통신 단말기의 멀티미디어 메시지 동작방법
US7630761B2 (en) * 2005-11-04 2009-12-08 Cardiac Pacemakers, Inc. Method and apparatus for modifying tissue to improve electrical stimulation efficacy
MX2008009830A (es) * 2006-06-20 2009-05-11 Isu Abxis Co Ltd Efecto del inhibidor bst2.
RU2322440C1 (ru) * 2006-09-21 2008-04-20 Российский химико-технологический университет (РХТУ им. Д.И. Менделеева) Замещенные омега-азолилалкананилиды, способ их получения и применение в качестве антиагрегантов
AU2008219007A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
EP2278879B1 (en) * 2008-04-21 2016-06-15 PATH Drug Solutions Compounds, compositions and methods comprising oxadiazole derivatives
US8759384B2 (en) * 2008-05-12 2014-06-24 David J. Bearss Oxo-imidazolyl compounds
JP2012503005A (ja) * 2008-09-19 2012-02-02 インスティテュート フォア ワンワールド ヘルス イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。
DE102009012314A1 (de) 2009-03-09 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
US20120258093A1 (en) 2009-08-20 2012-10-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
US20130337470A1 (en) 2010-10-25 2013-12-19 Biogen Idec Ma Inc. METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMadCAM LEVELS
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2022162164A1 (en) 2021-01-29 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL136473C (es) * 1968-02-19
CA2127462C (en) * 1992-01-13 1999-03-23 Roy R. Lobb Treatment for asthma
WO1993017033A1 (en) * 1992-02-19 1993-09-02 The Biomembrane Institute Inhibition of cell adhesion by chemically-defined oligosaccharides, their derivatives, mimetics, and antibodies directed thereto
DE4224414A1 (de) * 1992-07-24 1994-01-27 Cassella Ag Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung
CA2153228A1 (en) * 1993-01-08 1994-07-21 Shiu-Lan Ng Chiang Peptide inhibitors of cell adhesion
DE4427979A1 (de) * 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
WO1995015973A1 (en) * 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
AU2958195A (en) * 1994-06-29 1996-01-25 Texas Biotechnology Corporation Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
US5811391A (en) * 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) * 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
ATE212990T1 (de) * 1996-03-20 2002-02-15 Hoechst Ag Inhibitoren der knochenresorption und vitronectinrezeptor-antagonisten
DE19647382A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19741235A1 (de) * 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
SK152597A3 (en) 1998-06-03
AR010066A1 (es) 2000-05-17
CA2220822A1 (en) 1998-05-15
HRP970606A2 (en) 1998-08-31
JP4510160B2 (ja) 2010-07-21
RU2220977C2 (ru) 2004-01-10
EP0842944A3 (de) 1999-02-24
CN1193022A (zh) 1998-09-16
TW580501B (en) 2004-03-21
US6514952B1 (en) 2003-02-04
ES2202533T3 (es) 2004-04-01
PL323130A1 (en) 1998-05-25
BR9705726A (pt) 1999-07-20
PT842944E (pt) 2003-11-28
DE59710411D1 (de) 2003-08-14
MY118176A (en) 2004-09-30
HUP9702034A3 (en) 1998-12-28
HRP970606B1 (en) 2003-08-31
IL122186A0 (en) 1998-04-05
TR199701356A3 (tr) 1998-06-22
AU736595B2 (en) 2001-08-02
EP0842944B1 (de) 2003-07-09
ATE244725T1 (de) 2003-07-15
EP0842944A2 (de) 1998-05-20
JPH10147574A (ja) 1998-06-02
SK284349B6 (sk) 2005-02-04
AU4525797A (en) 1998-05-21
SI0842944T1 (en) 2004-02-29
HU9702034D0 (en) 1998-01-28
HUP9702034A2 (hu) 1998-07-28
TR199701356A2 (xx) 1998-06-22
IL122186A (en) 2003-05-29
CZ360097A3 (cs) 1998-06-17
PL188042B1 (pl) 2004-11-30
ZA9710245B (en) 1998-05-13
NO317242B1 (no) 2004-09-27
US5998447A (en) 1999-12-07
NO975245D0 (no) 1997-11-14
NO975245L (no) 1998-05-18
CZ292521B6 (cs) 2003-10-15
NZ329177A (en) 1998-11-25
DK0842944T3 (da) 2003-10-27
CN1133647C (zh) 2004-01-07
DE19647382A1 (de) 1998-05-20

Similar Documents

Publication Publication Date Title
MX9708781A (es) Heterociclos como inhibidores de la adhesion de leucocitos y antagonistas de vla-4.
MX9708782A (es) Heterociclos de 5 anillos como inhibidores de la adhesion de leucocitos y antagonistas de vla-4.
MX9708780A (es) Nuevos heterociclos como inhibidores de la adhesion de leucocitos y antagonistas de vla-4.
AU4037199A (en) Imidazolidine derivatives, the production thereof, their use and pharmaceutical preparations containing the same
MY118313A (en) Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
ES8704458A1 (es) Procedimiento para preparar derivados de almidoindol y amidoindazol.
KR950703945A (ko) 탁산 유도체를 함유하는 항종양 조성물(antitumour compositions containing taxane derivatives)
LV12209A (lv) Ar fenilgrupu aizvietoti heterocikli ka ciklooksigenazes-2 inhibitori
TR199902194T2 (xx) +p38 protein kinaz inhibit�rleri olarak ikameli azot ihtiva eden heterosikler.
ATE150000T1 (de) Einfluss von n,n,n-trimethylsphingosin auf die aktivität der protein-c-kinase, melanomzellwachstum in vitro, metastatisches potential in vivo und humane blutblättchenaggregation
BG101841A (bg) Инхибитори на клетъчна адхезия
IL114599A (en) Substituted pyrimidine compounds their preparation and pharmaceutical compositions containg them
NZ333591A (en) Thiazole compounds, process of manufacture and their use for treating prophylaxis and other diseases
MY121745A (en) 2,4-substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them.
ES2087038A1 (es) Nuevas piperidinas con actividad antagonista del paf.
MY134191A (en) Novel 5-membered ring heterocycles, their preparation their use and pharmaceutical preparations comprising them
CA2157792A1 (en) N-(3-piperidinyl-carbonyl)-beta-alanine derivatives as paf antagonists
GR3033862T3 (en) Angiotensin ii antagonists as a prophylactic or therapeutic drug for renal diseases.
EP1489081A4 (en) SPIRO DERIVATIVES AND INHIBITORS OF MEMBRANE MOLECULES CONTAINING THEM AS ACTIVE INGREDIENTS
MY129029A (en) Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them.
TWI256386B (en) Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
MXPA04000041A (es) Nuevos derivados de imidazolidina, su preparacion y su uso como antagonistas de vla-4.
EP0360130A3 (de) Elaiophylinderivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel und sie enthaltende Arzneimittel
TH42839A (th) เฮเทอโรไซเคิลชนิด 5 เมมเบอร์ริงชนิดใหม่, การเตรียมสารเหล่านั้น, การใช้สารเหล่านั้นและยาเตรียมทางเภสัชศาสตร์ที่ประกอบด้วยสารเหล่านั้น

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees